Novo Nordisk's Awiqli (insulin icodec-abae) has been approved by the FDA as the first once-weekly basal insulin for adults with type 2 diabetes, reducing the need for daily injections. The approval is based on the ONWARDS phase 3a clinical trials showing effective blood sugar control and a safety profile consistent with daily basal insulin. Novo Nordisk plans to launch Awiqli in the US in the second half of 2026, offering a new treatment option that fits patient preferences and routines. This approval reinforces Novo Nordisk's commitment to innovation and support for diabetes patients.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
